Human Genome Epidemiology Literature Finder
Records 1 - 11 (of 11 Records) |
Query Trace: Thrombocytopenia and BRCA1[original query] |
---|
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England journal of medicine 2009 Jul 361 (2): 123-34. Fong Peter C, Boss David S, Yap Timothy A, Tutt Andrew, Wu Peijun, Mergui-Roelvink Marja, Mortimer Peter, Swaisland Helen, Lau Alan, O'Connor Mark J, Ashworth Alan, Carmichael James, Kaye Stan B, Schellens Jan H M, de Bono Johann |
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. The Lancet. Oncology 2013 Aug 14 (9): 882-92. Sandhu Shahneen K, Schelman William R, Wilding George, Moreno Victor, Baird Richard D, Miranda Susana, Hylands Lucy, Riisnaes Ruth, Forster Martin, Omlin Aurelius, Kreischer Nathan, Thway Khin, Gevensleben Heidrun, Sun Linda, Loughney John, Chatterjee Manash, Toniatti Carlo, Carpenter Christopher L, Iannone Robert, Kaye Stan B, de Bono Johann S, Wenham Robert |
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology 2015 Jun 137 (3): 386-91. Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth |
Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 2017 8 23 (21): 6400-6410. Dhawan Mallika S, Bartelink Imke H, Aggarwal Rahul Raj, Leng Jim, Zhang Jenna Z, Pawlowska Nela, Terranova-Barberio Manuela, Grabowsky Jennifer A, Gewitz Andrew, Chien Amy J, Moasser Mark, Kelley Robin K, Maktabi Tayeba, Thomas Scott, Munster Pamela |
BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2017 Nov . Kotsopoulos Joanne, Willows Karla, Trat Sandra, Kim Raymond H, Volenik Alexandra, Sun Ping, Narod Steven A, Boyd Jeffrey, May Taym |
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. Oncotarget 2017 Oct 8 (45): 79175-79187. Lee Jung-Min, Hays John L, Chiou Victoria L, Annunziata Christina M, Swisher Elizabeth M, Harrell Maria I, Yu Minshu, Gordon Nicolas, Sissung Tristan M, Ji Jiuping, Figg William D, Minasian Lori, Lipkowitz Stanley, Wood Bradford J, Doroshow James, Kohn Elise |
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer 2018 Apr 124 (7): 1374-1382. O'Reilly Eileen M, Lee Jonathan W, Lowery Maeve A, Capanu Marinela, Stadler Zsofia K, Moore Malcolm J, Dhani Neesha, Kindler Hedy L, Estrella Hayley, Maynard Hannah, Golan Talia, Segal Amiel, Salo-Mullen Erin E, Yu Kenneth H, Epstein Andrew S, Segal Michal, Brenner Robin, Do Richard K, Chen Alice P, Tang Laura H, Kelsen David |
Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients? Gynecologic oncology 2019 May . Tomao Federica, Musacchio Lucia, Di Mauro Federica, Boccia Serena Maria, Di Donato Violante, Giancotti Antonella, Perniola Giorgia, Palaia Innocenza, Muzii Ludovico, Benedetti Panici Pierlui |
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology 2020 8 21 (10): 1269-1282. Diéras Véronique, Han Hyo S, Kaufman Bella, Wildiers Hans, Friedlander Michael, Ayoub Jean-Pierre, Puhalla Shannon L, Bondarenko Igor, Campone Mario, Jakobsen Erik H, Jalving Mathilde, Oprean Cristina, Palácová Marketa, Park Yeon Hee, Shparyk Yaroslav, Yañez Eduardo, Khandelwal Nikhil, Kundu Madan G, Dudley Matthew, Ratajczak Christine K, Maag David, Arun Banu |
Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2020 5 32 (2): 149-162. Wang Nan, Li Kun, Huang Wenfa, Kong Weiyao, Liu Xiaoran, Shi Weijie, Xie Feng, Jiang Hanfang, Song Guohong, Di Lijun, Wang Quanren, Yu Jianjun, Li Huipi |
Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer. Gynecologic oncology 2023 12 181 33-39. Ji Hyun Kim, Se Ik Kim, Eun Young Park, Eun Taeg Kim, Hyesu Kim, Sangeon Kim, Sang-Yoon Park, Myong Cheol L |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: